全尿多重下一代RNA测序检测用于早期发现侵袭性前列腺癌的研发
本研究开发了一种基于排尿后全尿样本的下一代RNA测序多重生物标志物检测(UPSeq),评估84个前列腺癌转录组标志物,并在109例极端设计队列中验证。UPSeq的15转录本模型在36例独立验证集中预测GG≥3前列腺癌的AUC为0.82,优于血清PSA和测序版MiPS(AUC均为0.69)。
要点
- UPSeq是一种检测排尿后全尿中84个前列腺癌RNA标志物的NGS多重检测。
- 在极端设计队列中,T2:ERG.T1E4和PCA3在良性和GG≥3前列腺癌间表达差异显著。
- 15转录本UPSeq模型预测GG≥3前列腺癌的AUC为0.82,优于PSA和MiPS的0.69。
核心结论
- UPSeq尿液RNA NGS检测有潜力辅助PSA改善侵袭性前列腺癌的早期发现。
研究设计与样本
- 临床前开发与验证研究,训练集73例,独立验证集36例,极端设计队列共109例(良性/GG1 vs GG≥3,排除GG2)。
主要发现
- UPSeq与MiPS分析准确性高且一致,可检测胚系HOXB13和体细胞SPOP突变表达。
- 极端设计队列中T2:ERG.T1E4中位归一化 reads 为1.2 vs 78.8(p < 0.00001),PCA3为1024 vs 2521(p = 0.02)。
- 15转录本模型在验证集(n=36)预测GG≥3前列腺癌AUC为0.82,优于血清PSA(0.69)和测序版MiPS(0.69)。
关键数值与推荐
- UPSeq模型基于84个前列腺癌转录组标志物,最终采用15转录本机器学习模型。
- 训练集n=73,验证集n=36,极端设计队列n=109。
临床怎么用
- UPSeq可作为PSA的补充手段,用于早期识别侵袭性前列腺癌高风险患者。
局限性
- 研究为临床前开发与验证,样本量有限(训练集73例,验证集36例)。
- 采用极端设计队列(排除GG2),可能影响结果在完整疾病谱中的外推性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Despite biomarker development advances, early detection of aggressive prostate cancer (PCa) remains challenging. We previously developed a clinical-grade urine test (Michigan Prostate Score [MiPS]) for individualized aggressive PCa risk prediction. MiPS combines serum prostate-specific antigen (PSA), the TMPRSS2:ERG (T2:ERG) gene fusion, and PCA3 lncRNA in whole urine after digital rectal examination (DRE). OBJECTIVE: To improve on MiPS with a novel next-generation sequencing (NGS) multibiomarker urine assay for early detection of aggressive PCa. DESIGN, SETTING, AND PARTICIPANTS: Preclinical development and validation of a post-DRE urine RNA NGS assay (Urine Prostate Seq [UPSeq]) assessing 84 PCa transcriptomic biomarkers, including T2:ERG, PCA3, additional PCa fusions/isoforms, mRNAs, lncRNAs, and expressed mutations. Our UPSeq model was trained on 73 patients and validated on a held-out set of 36 patients representing the spectrum of disease (benign to grade group [GG] 5 PCa). OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The area under the receiver operating characteristic curve (AUC) of UPSeq was compared with PSA, MiPS, and other existing models/biomarkers for predicting GG ≥3 PCa. RESULTS AND LIMITATIONS: UPSeq demonstrated high analytical accuracy and concordance with MiPS, and was able to detect expressed germline HOXB13 and somatic SPOP mutations. In an extreme design cohort (n = 109; benign/GG 1 vs GG ≥3 PCa, stratified to exclude GG 2 cancer in order to capture signal difference between extreme ends of disease), UPSeq showed differential expression for T2:ERG.T1E4 (1.2 vs 78.8 median normalized reads, p < 0.00001) and PCA3 (1024 vs 2521, p = 0.02), additional T2:ERG splice isoforms, and other candidate biomarkers. Using machine learning, we developed a 15-transcript model on the training set (n = 73) that outperformed serum PSA and sequencing-derived MiPS in predicting GG ≥3 PCa in the held-out validation set (n = 36; AUC 0.82 vs 0.69 and 0.69, respectively). CONCLUSIONS: These results support the potential utility of our novel urine-based RNA NGS assay to supplement PSA for improved early detection of aggressive PCa. PATIENT SUMMARY: We have developed a new urine-based test for the detection of aggressive prostate cancer, which promises improvement upon current biomarker tests.
引用
- Cani AK, Hu K, Liu CJ, et al. Development of a Whole-urine, Multiplexed, Next-generation RNA-sequencing Assay for Early Detection of Aggressive Prostate Cancer. Eur Urol Oncol. 2021. PMID: 33812851. doi:10.1016/j.euo.2021.03.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。